Multiple myeloma manifesting as an ocular salmon patch - a case report.

Multiple myeloma manifesting as an ocular salmon patch - a case report. Orbit. 2019 Nov 13;:1-4 Authors: Ben Artsi E, Barkley MR, Khong JJ, Mckelvie PA, McNab AA, Hardy TG Abstract Multiple myeloma (MM) is the second most prevalent hematologic malignancy after non-Hodgkin lymphoma and is currently considered incurable. Clinical ophthalmic manifestations of MM are rare but at the same time diverse. Ocular surface manifestations of multiple myeloma are uncommon.Conjunctival 'salmon patch' is a typical ocular surface ophthalmological sign with a distinct set of differential diagnoses, including most often ocular adnexal lymphoma.This case report presents a 33-year-old female with a relapse of MM manifesting as a conjunctival 'salmon patch'. The patient initially responded well to medical management including high dose melphalan supported by a third autologous stem cell transplantation (ASCT) and did not require further surgical excision of the ocular lesion. It is suggested that MM should be included in the differential diagnosis of 'salmon patch' conjunctival lesions. PMID: 31722590 [PubMed - as supplied by publisher]
Source: Orbit - Category: Opthalmology Authors: Tags: Orbit Source Type: research

Related Links:

High dose chemotherapy followed by autologous stem cell transplantation (ASCT) offers a cure in the relapsed setting in both Hodgkin (HL) and non-Hodgkin lymphoma (NHL). Additionally, it remains a first-line standard of care in multiple myeloma (MM) patients whom are eligible for ASCT. However, the management of these hematologic malignancies continues to rapidly evolve with non-cytotoxic therapeutic options such as development of new cellular therapies. These developments underscore the importance of monitoring immune reconstitution after ASCT.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 476 Source Type: research
Background: Patients undergoing hematopoietic stem cell transplantation (HSCT) have to worsen of functional capacity during hospitalization. However, it is not known whether the respiratory muscle strength is related to functional capacity.Objective: We hypothesized that functional capacity change is correlated to respiratory muscle strength changes in patients during hospitalization for HSCT.Methods: This is a prospective, observational study. Thirty one patients (18 males; 45 years) hospitalized for HSCT were eligible for this study. Respiratory muscle strength (Maximal Inspiratory Pressure - MIP and Maximal Expiratory P...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Physiotherapists Source Type: research
Publication date: Available online 2 October 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Avyakta Kallam, Julie M. VoseAbstractNon-Hodgkin lymphomas that are refractory to or relapse after frontline chemoimmunotherapy have a poor prognosis. Although high dose chemotherapy, followed by autologous stem cell transplantation remains the standard of care at relapse, this treatment modality leads to a cure in less than 50% of the patients. Adoptive cellular immunotherapy with anti CD 19 chimeric antigen receptor (CAR) T cell has changed the treatment landscape in B cell lymphomas. They have emerged as effective t...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ncey Jose M. Garcia Autologous hematopoietic stem cell transplantation (AHCT) is an accepted strategy for various hematologic malignancies that can lead to functional impairment, fatigue, muscle wasting, and reduced quality of life (QOL). In cancer cachexia, these symptoms are associated with inflammation, hypermetabolism, and decreased anabolic hormones. The relative significance of these factors soon after AHCT setting is unclear. The purpose of this study was to characterize the acute effects of AHCT on physical function, body composition, QOL, energy expenditure, cytokines, and testosterone. Outcomes were assesse...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Authors: Yang X, Wan M, Yu F, Wang Z Abstract Plerixafor in combination granulocyte-colony stimulating factor (G-CSF) has been used for the mobilization of hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). The aim of this study was to systematically search the published literature and analyze evidence on the efficacy of additional plerixafor for successful HSC mobilization in patients with NHL and MM, and to evaluate the safety of the drug. The PubMed, Scopus, Cochrane Central Regist...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
Autologous hematopoietic cell transplantation (Auto-HCT) following high dose chemotherapy has an important role in treating many patients with lymphoma and multiple myeloma. For patients with a variety of lymphomas including Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL), Auto-HCT might potentially be a curative procedure, in addition to improving overall survival (OS) and progression free survival (PFS) [1-5]. For multiple myeloma, Auto-HCT is not curative, but its role is well-established as a consolidation treatment to achieve deep durable remissions in the majority of patients [6-9].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Autologous hematopoietic cell transplantation (auto-HCT) following high-dose chemotherapy has an important role in treating many patients with lymphoma and multiple myeloma. For patients with a variety of lymphomas, including Hodgkin disease (HD) and non-Hodgkin lymphoma (NHL), auto-HCT might potentially be a curative procedure, in addition to improving overall survival and progression-free survival [1 –5]. For multiple myeloma, auto-HCT is not curative, but its role is well established as a consolidation treatment to achieve deep durable remissions in most patients [6–9].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Publication date: Available online 30 March 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Young-Woo Jeon, Seugyun Yoon, Gi June Min, Sung-Soo Park, Silvia Park, Jae-Ho Yoon, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Seok Lee, Chang-Ki Min, Jong Wook Lee, Seok-Goo ChoAbstractIntroductionAllogeneic hematopoietic stem cell transplant with reduced-intensity conditioning is an effective therapeutic option for patients with refractory or relapsed aggressive non-Hodgkin lymphoma (NHL).Patients and MethodsWe retrospectively evaluated survival outcomes and the efficacy of our fludarabine/mel...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Discussion In this section, we discuss the mechanisms responsible for lymphomagenesis in the various inborn errors of immunity and provide an overview of the treatment. Defects in Immune Responses That Predispose to Lymphomagenesis in PIDDs The complex immune mechanisms and their interplay that predisposes to neoplastic transformation of B or T cells and development of lymphomas in PIDD patients has not been fully elucidated. However, it is expected that the etiology in most cases is multifactorial and related to a dynamic regulation of immune response and environmental triggers (Figure 3). An underlying intrinsic susce...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Conclusions: CAR T cell therapies have demonstrated the clinical benefits of harnessing our body's own defenses to combat tumor cells. Similar research is being conducted on lesser known modifications and gene-modified immune cells, which we highlight in this review. Introduction Chimeric antigen receptors and engineered T cell receptors (based on previously identified high affinity T cell receptors) function by redirecting T cells to a predefined tumor-specific (or tumor-associated) target. Most of these modifications use retroviral or lentiviral vectors to integrate the construct, and most of the receptors ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Hematology | Lymphoma | Myeloma | Non-Hodgkin's Lymphoma | Opthalmology | Stem Cell Therapy | Stem Cells | Transplants